•Developed
a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful
in pharmacodynamic
testing to inform targeted anti-cancer chemotherapy development and clinical
monitoring
•CD133
is a cell surface glycoprotein used as a marker and expressed in stem cells
such as hematopoietic stem cells, endothelial progenitor cells and neural stem
cells
•The
resulting
antibodies recognize both glycosylated and non-glycosylated regions of the
cognate antigen
•The
inventors have demonstrated the utility of this invention in immunofluorescence
assay, western blotting and ELISA, flow cytometry, and immunoprecipitation